Researchers are reporting that a new vaccine designed to treat breast cancer appears to be safe in women with advanced disease. It showed signs of slowing down tumor growth too.

The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast cancer, which affects 20 to 30 percent of breast cancer patients. Using immune cells from a cancer patient's own body, Neuvenge is a tailor-made therapy.

Reports about Neuvenge, published in the Journal of Clinical Oncology, indicate the vaccine did not cause any serious side effects and of the 18 women who participated in the Phase I study, there was a reduction in the size of a tumor in one patient. In three other women, the disease seemed to stabilize for as long as a year.

A study published in the journal Cancer says that improvements in the treatment of metastatic breast cancer are making a difference and patients are living longer with the disease.

Researchers in Canada conducted a study evaluating 2,000 women diagnosed with advanced breast cancer. The time periods in the study were broken up into four groups dating from 1991 until 2001. The researchers concluded that one year survival improved from 55 percent to 71 percent and two year survival improved from 33 percent to 45 percent.

The introduction of new chemotherapy drugs, new approaches to hormonal therapy, and new targeted therapy have been introduced over the period of time evaluated in the study.

Tykerb (lapatinib) may be effective at shrinking breast cancer tumors in the brain, researchers say. This drug is called a targeted therapy because it can kill cancer cells and leave normal cells alone. Tykerb targets HER2 and EGFR, two proteins that function abnormally in breast cancer cells.

A study was conducted that included 241 breast cancer patients with brain metastasis that continued to progress after radiation treatment and Herceptin therapy.

The study concluded that nearly half of the patients, 46 percent, experienced at least a twenty percent reduction in the size the the brain tumors.

The researchers concluded "Tykerb has promise in the treatment of brain metastasis".

Tarceva (erlotinib) and Iressa (gefitnib) are both agents targeted against the EGFR pathway. This pathway is involved in cell growth and replication and when mutated or altered, excessive replication of cells can occur. These agents reduce the uncontrolled replication and growth of cancer cells by blocking mutated EGFR pathways.

According to an article published in the Journal of Clinical Oncology, the targeted agent Tarceva may provide anticancer responses for patients with non-small cell lung cancer (NSCLC) who stop responding to Iressa. These drugs are not associated with the side effects of chemotherapy, providing an effective alternative for patients who are not eligible for standard therapy.

A study was done to evaluate the effectiveness of Tarceva among patients who stopped responding to Iressa. The researchers concluded that -- Patients with NSCLC who demonstrate disease control with Iressa and do not have EGFR mutations appear to have benefit from treatment with Tarceva once their cancer progresses following their treatment with Iressa. Patients with recurrent NSCLC may wish to speak with their physician regarding their individual risks and benefits of treatment with Tarceva.

Axitinib is an agent that targets angiogenesis -- blood supply to a tumor. It disrupts blood vessels that grow and provide nutrients to cancer cells. Without the nutrients and oxygen supplied by blood vessels, cancer cells cannot grow or replicate.

Researchers conducted a trial to evaluate axitinib in the treatment of metastatic breast cancer. Patients were either given Taxotere or Taxotere plus axitinib. Anticancer responses were achieved in 40 percent of patients treated with the addition of axitinib to Taxotere, compared with only 23 percent of patients treated with Taxotere alone.

The researchers concluded -- that the addition of axitinib to Taxotere improves anticancer responses and delays cancer progression compared to Taxotere alone in the treatment of metastatic breast cancer.

David Foster was diagnosed with Advanced Renal Cell Carcinoma in April 2005. Translation: stage four kidney cancer and the sixth deadliest form of cancer. Not a great disease to acquire. Also not the end of the world. Just ask David who is busy working as a National Strategic Advisor in Augusta, Georgia, headlining within the independent magazine community, hanging out with dog Gracie, and documenting his journey in a blog he calls David Foster's Kicking Kidney Cancer's Arse.

He's no wimp, this guy. Just read his June 23 post, titled May kill me, but it ain't gonna beat me. He didn't let that hard-nosed kid Jerry whip him when he was eight -- he smacked him so hard in the lunchroom, Jerry was left stumbling and bleeding -- and he won't let cancer bully him either. Still, David admits: he is sick. He explains it all in a post he calls Mr. Foster, are you really sick?

David got an e-mail one day. It read, Mr. Foster, are you really sick? I read your blog and you don't sound sick.

A report published in the Journal of the National Cancer Institute has stated that cisplatin has better response rates than carboplatin in the treatment of advanced non-small cell lung cancer.

The two main types of lung cancer, accounting for over 90 percent of all lung cancers, are non-small cell and small cell cancer. Non-small cell lung cancer (NSCLC) accounts for most of that 90 percent.

Advanced NSCLC means that the patient's cancer has spread to other organs or areas of the body. There has been research done to evaluate which drug is better for NSCLC -- cisplatin or carboplatin. Nine clinical trials were analyzed to see what regime is a better treatment option.

A late-breaking session at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) says that "Patients with colorectal cancer whose cancer has spread to the liver have improved survival without cancer recurrences when they receive chemotherapy prior to and following surgery, compared to those treated with surgery only."

Adjuvant chemotherapy is when chemo is used after surgery. Neoadjuvant treatment is when chemotherapy is given to shrink the tumor to allow for better surgical removal.

The second leading cause of cancer-related deaths in the United States is colorectal cancer. Liver metastasis is common among patients with advanced disease. A clinical trial was conducted to evaluate the use of chemotherapy before and after surgery compared to surgery alone. The trial included 364 patients who were divided into two treatment groups.

At nearly four years' followup, recurrence-free survival was 42.4 percent for patients receiving chemotherapy before and after surgery, compared with only 33.2 percent for those treated with surgery only.

Arsenic trioxide sold under the brand name Trisenox, is approved for patients with a rare leukemia named acute promyelocytic leukemia (APL).

APL is a form of acute myeloid leukemia, about 1,500 people are diagnosed every year with this rare disease. Standard treatment involves chemotherapy and a form of vitamin A -- alltrans retinoic acid. This therapy helps about 70-80 percent of patient gain long term-remissions. About 25 percent of patients do relapse and are no longer responsive to treatment.These patients often are treated with arsenic trioxide.

A study was sponsored by The National Cancer Institute to see if the addition of arsenic trioxide along with the standard therapy for first line treatment would prove better survival rates.

Interferon is an immune stimulating agent. According to an article recently published in the Annals of Surgery, administration of interferon following surgery may improve survival among patients with advanced hepatitis B-related hepatocelluar carcinoma.

Hepatocelluar carcinoma (HCC) is the most common type of liver cancer. Unfortunately for this disease, recurrences often happen after surgical removal of the cancer. Researchers continue to evaluate ways to reduce these recurrences.

A clinical trial was conducted to evaluate the use of interferon following surgery in patients with HCC. The trial included 80 patients, one group received the interferon after surgery and the other group received no further treatment. The researchers found that the group treated with interferon experienced better survival rates.

Join Living Beyond Breast Cancer (LBBC) for a free educational teleconference titled Medical and Quality-of-Life Updates from the 43rd Annual Meeting of the American Society of Clinical Oncology.

The teleconference will be held on Monday, June 11, 2007 at 12:00 p.m. - 1:30 p.m. (EDT). You can participate by using any telephone or by computer using Real Network Player or Windows Media Player. Register online at www.lbbc.com or call 610-645-4567.

This teleconference brings to you groundbreaking research presented at the largest annual conference of cancer professionals in the United States. Some topics discussed will be:

• Advances in surgical, hormonal and chemotherapy treatments
• Using diet and nutrition to improve quality of life
• Clinical trials measuring the long-term impact of treatment on health and well-being
• New information on how to treat and manage metastatic breast cancer

Following the speaker presentation there will be an interactive question and answer session.

Chemotherapy given before surgery to remove cancer is called neoadjuvant treatment. An oncologist might recommend this based of the size of the tumor -- it being very large. The idea is to shrink the tumor and then have surgery to remove the cancer.

Having chemotherapy administered while the tumor is still there can show what drugs are working and what drugs have no effect on the tumor. Chemotherapy when started immediately, not after surgery with healing time needed, gives the patient systematic treatment right away. This could be beneficial and is why physicians might recommend this form of treatment. The truth is they don't know if it is better or not.

Of course, every case of breast cancer is different. We all need to make tough decisions regarding our treatment plan. The facts are that currently there is no evidence that survival is improved with neoadjuvant verses adjuvant (after surgery) chemotherapy in women with locally advanced breast cancer.

The clinical trials that are done help physicians understand what treatments are more effective. Results from a Phase II clinical trial was published in the Journal of Clinical Oncology. It stated that neoadjuvant treatment with Taxotere, Navelbine, and Herceptin resulted in a complete disappearance of detectable cancer in 39 percent of women with locally advanced HER2 positive breast cancer.

The study showed that after two years followup, on the thirty one women with locally advanced breast cancer involved in the study, the overall survival was 97 percent and cancer free survival was 84 percent.

So, the message here is that, even though the study group was small, the results showed a good response to this treatment plan.

There's so much more to life than money. At the same time, the daily grind definitely depends some on this coveted staple. For one man, whose life did depend on money, it could have been everything. But it wasn't.

Think about this:

Wayne Schenk won $1 million in the New York lottery on January 12 after purchasing a $5 scratch-off ticket. His jackpot win came just five weeks after his diagnosis of inoperable lung cancer was delivered. His one wish: to receive a lump sum so he could receive specialized treatment for his advanced disease.

Lottery officials claim they were sympathetic but just couldn't give him a lump sum. The best they could do was issue him $50,000 annual installments for 20 years.

Schenk, 51, only survived for a little more than one year. He died on April 23 at the Veterans Administration Hospital in Syracuse. At the time of his death, he had received just $34,000.

So money isn't everything. But could it have been?

Surely, everyone can benefit in some way from yoga. Women with breast cancer that has spread beyond the breast, however, may benefit greatly from a tailored program featuring gentle yoga postures, breathing exercises, and meditation.

The great benefits: less pain and fatigue and more vigor, relaxation, and acceptance," says Dr. James W. Carson from Duke University Medical Center and lead of a study published in the Journal of Pain and Symptom Management.

Carson says women with advanced breast cancer need effective methods for curbing cancer-related symptoms.

The pilot study included 13 women who attended yoga classes once per week for eight weeks. The women, with an average age of 59 and with diagnoses occurring an average of seven years earlier, were helped significantly. They felt more invigorated and gained a greater sense of acceptance. They also found they felt better not only on the day they practiced yoga but the next day too.

This study offers the first, small-scale evidence for yoga's potential benefits for women with limited life expectancy.

In the news there has been a lot of questioning whether or not it is wise for someone diagnosed with cancer, and needs therapy or treatments to control their cancer, should still work or carry on with their life the way it was before cancer entered into their lives.

Its a good question -- but all cancer survivors or patients must make this decision themselves and should not be judged either way. Treatments can be physically mild or debilitating and everywhere in between.

I know women who are walking in Elizabeth Edward's shoes and have metastatic breast cancer. These women that I know might not be blazing the campaign trail but they are still keepin-on- keepin-on with life like it was before their breast cancer returned. They still get up and go to work, do the laundry, feed their children, all the normal things that you and I do everyday. Not to say that days can't be really tough, emotionally and physically. But I see women who are living with the disease -- really living and not giving up any of their dreams.

I can't really speak for women with metastatic disease, I can only talk about what I see, because I am not walking in their shoes and don't completely understand what it is like living with recurrent breast cancer.

Recurrent breast cancer can mean being on some kind of cancer treatment for the rest of your life, it can mean long times of remission or no evidence of disease.

Can it mean Elizabeth Edwards being first lady with metastatic breast disease? I think so.